Pulmonary EmbolismRELAX-PENCT02601846
Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study
An observational study of Pulmonary Embolism, run by University Hospital, Geneva at 10 sites in 3 countries.
Trial summary
A multicentre multinational prospective management outcome study has recently proven the safety of a diagnostic strategy combining clinical probability assessment with an age-adjusted D-dimer cut-off, defined as a value of (age x 10) in patients > 50 years, for ruling out PE in outpatients, with a very low likelihood… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pulmonary Embolism
- How many people
- 1,507 participants
- Where
- 10 sitesin 3 countries
- Study dates
- Nov 2015to Jun 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All consecutive patients admitted to the emergency department with suspected PE defined as acute onset of new or worsening shortness of breath or chest pain without any other obvious etiology in whom PE has been considered ruled out by negative D-dimers using an age-adjusted cut-off will be screened for inclusion. Those with non-high probability and negative D-dimer (PE excluded by the non-invasive strategy using "new" D-dimer cut-off) will be included and followed-up for 3 months. The aim of including both patients above and under 50 years of age is to be able to compare the difference in thromboembolic event rates between patients with a D-dimer level between 500 µg/L and their age-ajusted cut-off and those with a D-dimer < 500 µg/L.
Who may be able to join
- Consecutive out patients with suspected PE in whom PE has been considered ruled out by negative D-dimers using an age-adjusted cut-off.
Who cannot join
- Life expectancy less than 3 months.
- Geographic inaccessibility for follow-up.
- Therapeutic anticoagulation for any indication.
- Pregnancy.
- Age less than 18.
Trial locations and contacts
10 sites in 3 countries.
10 sites in 3 countries
France5 sites
Albert Trinh-Duc
Agen
Angers Univeristy Hospital
Angers
Brest University Hospital
Brest
Jeannot Schmidt
Clermont-Ferrand
Guy Meyer
Paris
Switzerland4 sites
Hôpital Fribourgeois HFR
Fribourg
Geneva University Hospitals
Geneva
Centre Hospitalier Universitaire Vaudois
Lausanne
Groupement Hospitalier de l'Ouest Lémanique
Nyon
About this study
A multicentre multinational prospective management outcome study has recently proven the safety of a diagnostic strategy combining clinical probability assessment with an age-adjusted D-dimer cut-off, defined as a value of (age x 10) in patients > 50 years, for ruling out PE in outpatients, with a very low likelihood of subsequent symptomatic VTE. Moreover, this study showed that such a strategy increased the diagnostic yield of D-dimers, as it allowed ruling out PE without further investigation in a significantly higher proportion of patients than when using standard cut-off, particularly so in patients 75 years or older.
The objective of the present study is to confirm in a prospective cohort of "real life" patients the usefulness of the age-adjusted D-dimer cut-off to rule out PE in patients presenting to the emergency department with suspected PE.
Read the detailed description
BACKGROUND
PE diagnostic strategies Pulmonary embolism (PE) is a frequently suspected diagnosis in the emergency room (ER) in patients presenting with shortness of breath and/or chest pain without any obvious cause identified. Historically, PE diagnosis required a pulmonary angiography, a costly and invasive procedure with associated morbidity and even mortality. Over the last 25 years, evolving diagnostic strategies have been developed and widely validated in prospective multicentre management outcome studies, with the aim of confirming or excluding the diagnosis of PE safely enough to avoid realising pulmonary angiography. Nowadays, PE diagnosis therefore relies on diagnostic strategies, including sequential evaluation of clinical probability, measurement of plasma D-dimer levels and most often CT pulmonary angiogram (CTPA), rather than a standalone test.
The initial and essential step is the assessment of pre-test clinical probability, either by gestalt or by validated clinical prediction rules (Wells rule of Geneva score). This initial evaluation separates patients into different groups of PE prevalence, and thus directly influences the negative and positive predictive values of the diagnostic tests used in these patients.
D-dimer measurement Plasma D-dimer measurement has been extensively evaluated for the exclusion of PE in outpatients. The diagnostic usefulness of D-dimers lies in their high sensitivity and hence their capacity to exclude PE when below a certain cut-off ("negative D-dimers") without further investigations. Indeed, in patients with "non-high" clinical probability (low and intermediate groups in a three category score or unlikely group in a dichotomic score), a highly sensitive negative D-dimer test safely excludes PE without additional investigations. Sensitive D-dimer tests include those performed by the ELISA technique (median sensitivity 99%; Vidas®, Stratus®, AxSYM®) and by quantitative latex methods (median sensitivity 96%; STA Liatest®, Tinaquant®). In patients with high clinical probability or likely PE, the negative predictive value of even a highly sensitive D-dimer test will be insufficient to exclude PE. D-dimer measurement is thus not used in these patients.
Performance of D-dimers in elderly patients The specificity of the ELISA and quantitative latex D-dimer tests for venous thromboembolism (VTE) is limited, ranging from 35 to 40%. Indeed, D-dimers increase in various clinical situations, including cancer, infectious or inflammatory states, pregnancy or during post-operative periods, but also with age, leading to reduced specificity of the test in elderly patients. In other words, the probability of having a negative test result is reduced, so that the number of patients needed to test (NNT) to exclude one PE without further investigations is higher. Indeed, whereas PE can be ruled out in presence of non-high clinical probability and negative D-dimers in one out of 3 outpatients presenting to the emergency room with suspected PE, it can be excluded in only one out of 20 patients > 80 years. As current diagnostic strategies for PE include imaging (most often CTPA) in patients with positive D-dimers, lack of specificity of D-dimers in the elderly leads to a high proportion of these patients undergoing CTPA.
Age-adjusted D-dimer cut-off The question of a higher D-dimer cut-off in elderly patients was raised a decade ago, but studies confirming the potential security of such a strategy by retrospectively applying age-adjusted cut-offs to large prospective cohorts of consecutive patients with suspected VTE were published between 2010 and 2012 and confirmed the safety of using age-adjusted cut-offs on an overall population of several thousands of patients.
A progressive age-adjusted D-dimer cut-off (agex10 microg/L in patients > 50 years) was retrospectively derived and validated in a sample of 1712 patients with suspected PE. The retrospective validation study showed that the age-adjusted cut-off could increase by around 20% the number of patients in whom the D-dimer test was considered negative, without increasing the proportion of false-negative results when compared to the standard cut-off (<500 microg/L). The increase in the diagnostic yield of D-dimers was particularly pronounced in patients over 80 years, as the age-adjusted cut-off allowed an increase in the proportion of "negative" D-dimers from 9% to 21%, without any false negative result.
This progressive age-adjusted D-dimer cut-off has been prospectively validated in the ADJUST-PE study, a large multicentre multinational (19 centres in Belgium, France, the Netherlands, and Switzerland) management outcome study published at the beginning of this year. All consecutive patients who presented to the emergency department with clinically suspected PE were assessed by a sequential diagnostic work-up using clinical probability assessment (by one of the two following scores: simplified, revised Geneva score or the two-level Wells score for PE), highly sensitive D-dimer measurement (ELISA or immuno-turbidimetric assays), and CTPA. Patients with a D-dimer level below their age-adjusted cut-off did not undergo further investigations and were thus left without anticoagulant treatment and followed-up for a period of 3 months.
The ADJUST-PE study included a total of 3346 patients with suspected PE, from whom 22 were excluded (D-dimers not performed in 21 and 1 consent withdrawal), leaving 3324 patients included for the analysis. The subgroup of particular interest was of course patients having D-dimer levels between 500 microg/L and their age-adjusted cut-off (n=337). None of these patients was lost to follow-up and 6 patients received therapeutic anticoagulation for another indication than VTE. Of the remaining 331, 7 died and 7 had suspected VTE. Only one of these 14 events was adjudicated as confirmed VTE (nonfatal PE). The so-called "failure-rate" of the age-adjusted cut-off was thus very low at 1 / 331 (0.3%; 95% CI 0.1%-1.7%), so that this strategy can be considered as very safe.
In the ADJUSt-PE study, the overall number of patients ≥ 75 years was 766, of whom 673 had non-high clinical probability (87.9%). Among these 673 patients, the proportion of patients with D-dimer levels <500 microg/L was 43/673 (6.4%; 95% CI 4.8%-8.5%). Additional 157/673 patients (23.3%) had D-dimer levels below their age-adjusted cut-off. This means that among the patients ≥ 75 years with suspected PE and non-high clinical probability, 200/673 (29.7%; 95% CI 26.4%-33.3%) had a "negative" D-dimer result when age-adjusted cut-off was used. After excluding 5 of these patients who received anticoagulation for another indication, none of the remaining 195 patients experienced confirmed VTE during the 3 month follow-up (0.0%; 95% CI 0.0%-1.9%). The diagnostic yield of D-dimers was thus particularly increased by using an age-adjusted cut-off in patients ≥ 75 years, as the number of patients needed to test to exclude one PE diminished from 16 with conventional cut-off to 3.4 with age-adjusted cut-off, a figure that corresponds to the NNT in the general population in previous studies.
Increasing the proportion of patients in whom PE can be ruled out based on clinical probability assessment and D-dimer measurement without further testing is particularly interesting in older patients. Indeed, the higher prevalence of renal failure in this population increases the potential risk of contrast-induced nephropathy related to CTPA or even contra-indicates this test, and ventilation-perfusion lung scan (which can be performed in patients with severe renal failure) provides a high proportion of inconclusive results in older patients. Moreover, ruling out PE based on clinical probability and a simple blood test could contribute to reduce the time spent in the emergency department and the costs related to PE diagnostic work-up. Indeed, a previous study had shown that D-dimer measurement with conventional cut-off was highly cost-saving in patients less than 80 years, but not in patients over 80 years. Using an age-adjusted D-dimer cut-off dramatically increases the proportion of patients in whom PE can be ruled out and is thus highly likely to reduce the costs of PE diagnosis in the emergency department.
- Conditions
- Pulmonary Embolism
- Being tested
- No intervention
- Medical subject headings
- Pulmonary Embolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
This is an observational study, without any specific intervention.
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence of symptomatic thromboembolic events during follow-up in patients with PE excluded based on a negative D-dimer using the age-adjusted cutoff
Adjudicated objectively confirmed pulmonary embolism and/or deep vein thrombosis
Measured: Three months
Secondary outcomes (1)
Additional diagnostic yield of the age-adjusted D-dimer cut-off compared with the standard cut-off of 500µg/L
Proportion of patients with a non-high clinical probability and a D-dimer result between 500µg/L and their age-adjusted cut-off value
Measured: Three months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2015 (estimated)
- Study startNov 2015
- Primary completionJun 2019
- Study completionJun 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Pulmonary EmbolismStudies of the same condition, open and under way.
- More trials run by University Hospital, GenevaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,507 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Geneva
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital, Brest, European Georges Pompidou Hospital, University Hospital St Luc, Brussels, Centre Hospitalier Universitaire Vaudois, University Hospital, Angers, Centre Hospitalier d'Agen, University Hospital, Clermont-Ferrand
- Responsible party
- Principal investigator, Helia Robert-Ebadi, University Hospital, Geneva
- Investigators
- Helia Robert-Ebadi, MD, Principal investigator, Geneva University Hospitals and Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02601846
- Sponsor's protocol ID
- Geneva 15-010
- Acronym
- RELAX-PE
- Status last verified
- May 2021
- First submitted
- 14 Sep 2015
- Last updated
- 6 May 2021
- Results posted
- No
- Data monitoring committee
- No
Publications
Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le Gal G. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014 Mar 19;311(11):1117-24. doi: 10.1001/jama.2014.2135.
PubMed 24643601Robert-Ebadi H, Robin P, Hugli O, Verschuren F, Trinh-Duc A, Roy PM, Schmidt J, Fumeaux T, Meyer G, Hayoz D, Carron PN, Salaun PY, Sarasin F, Rutschmann O, Le Gal G, Righini M. Impact of the Age-Adjusted D-Dimer Cutoff to Exclude Pulmonary Embolism: A Multinational Prospective Real-Life Study (the RELAX-PE Study). Circulation. 2021 May 4;143(18):1828-1830. doi: 10.1161/CIRCULATIONAHA.120.052780. Epub 2021 May 3. No abstract available.
PubMed 33939529
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study
- ClinicalTrials.gov ID
- NCT02601846
- Acronym / sponsor ID
- RELAX-PE / Geneva 15-010
- Conditions
- Pulmonary Embolism
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,507 participants (actual)
- Lead sponsor
- University Hospital, GenevaUniversity, hospital or other
- Collaborators
- University Hospital, Brest, European Georges Pompidou Hospital, University Hospital St Luc, Brussels, Centre Hospitalier Universitaire Vaudois, University Hospital, Angers, Centre Hospitalier d'Agen, University Hospital, Clermont-Ferrand
- Study start
- Nov 2015
- Primary completion
- Jun 2019 (actual)
- Study completion
- Jun 2019 (actual)
- First posted
- 10 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A multicentre multinational prospective management outcome study has recently proven the safety of a diagnostic strategy combining clinical probability assessment with an age-adjusted D-dimer cut-off, defined as a value of (age x 10) in patients > 50 years, for ruling out PE in outpatients, with a very low likelihood of subsequent symptomatic VTE. Moreover, this study showed that such a strategy increased the diagnostic yield of D-dimers, as it allowed ruling out PE without further investigation in a significantly higher proportion of patients than when using standard cut-off, particularly so in patients 75 years or older.
The objective of the present study is to confirm in a prospective cohort of "real life" patients the usefulness of the age-adjusted D-dimer cut-off to rule out PE in patients presenting to the emergency department with suspected PE.
Detailed description
BACKGROUND
PE diagnostic strategies Pulmonary embolism (PE) is a frequently suspected diagnosis in the emergency room (ER) in patients presenting with shortness of breath and/or chest pain without any obvious cause identified. Historically, PE diagnosis required a pulmonary angiography, a costly and invasive procedure with associated morbidity and even mortality. Over the last 25 years, evolving diagnostic strategies have been developed and widely validated in prospective multicentre management outcome studies, with the aim of confirming or excluding the diagnosis of PE safely enough to avoid realising pulmonary angiography. Nowadays, PE diagnosis therefore relies on diagnostic strategies, including sequential evaluation of clinical probability, measurement of plasma D-dimer levels and most often CT pulmonary angiogram (CTPA), rather than a standalone test.
The initial and essential step is the assessment of pre-test clinical probability, either by gestalt or by validated clinical prediction rules (Wells rule of Geneva score). This initial evaluation separates patients into different groups of PE prevalence, and thus directly influences the negative and positive predictive values of the diagnostic tests used in these patients.
D-dimer measurement Plasma D-dimer measurement has been extensively evaluated for the exclusion of PE in outpatients. The diagnostic usefulness of D-dimers lies in their high sensitivity and hence their capacity to exclude PE when below a certain cut-off ("negative D-dimers") without further investigations. Indeed, in patients with "non-high" clinical probability (low and intermediate groups in a three category score or unlikely group in a dichotomic score), a highly sensitive negative D-dimer test safely excludes PE without additional investigations. Sensitive D-dimer tests include those performed by the ELISA technique (median sensitivity 99%; Vidas®, Stratus®, AxSYM®) and by quantitative latex methods (median sensitivity 96%; STA Liatest®, Tinaquant®). In patients with high clinical probability or likely PE, the negative predictive value of even a highly sensitive D-dimer test will be insufficient to exclude PE. D-dimer measurement is thus not used in these patients.
Performance of D-dimers in elderly patients The specificity of the ELISA and quantitative latex D-dimer tests for venous thromboembolism (VTE) is limited, ranging from 35 to 40%. Indeed, D-dimers increase in various clinical situations, including cancer, infectious or inflammatory states, pregnancy or during post-operative periods, but also with age, leading to reduced specificity of the test in elderly patients. In other words, the probability of having a negative test result is reduced, so that the number of patients needed to test (NNT) to exclude one PE without further investigations is higher. Indeed, whereas PE can be ruled out in presence of non-high clinical probability and negative D-dimers in one out of 3 outpatients presenting to the emergency room with suspected PE, it can be excluded in only one out of 20 patients > 80 years. As current diagnostic strategies for PE include imaging (most often CTPA) in patients with positive D-dimers, lack of specificity of D-dimers in the elderly leads to a high proportion of these patients undergoing CTPA.
Age-adjusted D-dimer cut-off The question of a higher D-dimer cut-off in elderly patients was raised a decade ago, but studies confirming the potential security of such a strategy by retrospectively applying age-adjusted cut-offs to large prospective cohorts of consecutive patients with suspected VTE were published between 2010 and 2012 and confirmed the safety of using age-adjusted cut-offs on an overall population of several thousands of patients.
A progressive age-adjusted D-dimer cut-off (agex10 microg/L in patients > 50 years) was retrospectively derived and validated in a sample of 1712 patients with suspected PE. The retrospective validation study showed that the age-adjusted cut-off could increase by around 20% the number of patients in whom the D-dimer test was considered negative, without increasing the proportion of false-negative results when compared to the standard cut-off (<500 microg/L). The increase in the diagnostic yield of D-dimers was particularly pronounced in patients over 80 years, as the age-adjusted cut-off allowed an increase in the proportion of "negative" D-dimers from 9% to 21%, without any false negative result.
This progressive age-adjusted D-dimer cut-off has been prospectively validated in the ADJUST-PE study, a large multicentre multinational (19 centres in Belgium, France, the Netherlands, and Switzerland) management outcome study published at the beginning of this year. All consecutive patients who presented to the emergency department with clinically suspected PE were assessed by a sequential diagnostic work-up using clinical probability assessment (by one of the two following scores: simplified, revised Geneva score or the two-level Wells score for PE), highly sensitive D-dimer measurement (ELISA or immuno-turbidimetric assays), and CTPA. Patients with a D-dimer level below their age-adjusted cut-off did not undergo further investigations and were thus left without anticoagulant treatment and followed-up for a period of 3 months.
The ADJUST-PE study included a total of 3346 patients with suspected PE, from whom 22 were excluded (D-dimers not performed in 21 and 1 consent withdrawal), leaving 3324 patients included for the analysis. The subgroup of particular interest was of course patients having D-dimer levels between 500 microg/L and their age-adjusted cut-off (n=337). None of these patients was lost to follow-up and 6 patients received therapeutic anticoagulation for another indication than VTE. Of the remaining 331, 7 died and 7 had suspected VTE. Only one of these 14 events was adjudicated as confirmed VTE (nonfatal PE). The so-called "failure-rate" of the age-adjusted cut-off was thus very low at 1 / 331 (0.3%; 95% CI 0.1%-1.7%), so that this strategy can be considered as very safe.
In the ADJUSt-PE study, the overall number of patients ≥ 75 years was 766, of whom 673 had non-high clinical probability (87.9%). Among these 673 patients, the proportion of patients with D-dimer levels <500 microg/L was 43/673 (6.4%; 95% CI 4.8%-8.5%). Additional 157/673 patients (23.3%) had D-dimer levels below their age-adjusted cut-off. This means that among the patients ≥ 75 years with suspected PE and non-high clinical probability, 200/673 (29.7%; 95% CI 26.4%-33.3%) had a "negative" D-dimer result when age-adjusted cut-off was used. After excluding 5 of these patients who received anticoagulation for another indication, none of the remaining 195 patients experienced confirmed VTE during the 3 month follow-up (0.0%; 95% CI 0.0%-1.9%). The diagnostic yield of D-dimers was thus particularly increased by using an age-adjusted cut-off in patients ≥ 75 years, as the number of patients needed to test to exclude one PE diminished from 16 with conventional cut-off to 3.4 with age-adjusted cut-off, a figure that corresponds to the NNT in the general population in previous studies.
Increasing the proportion of patients in whom PE can be ruled out based on clinical probability assessment and D-dimer measurement without further testing is particularly interesting in older patients. Indeed, the higher prevalence of renal failure in this population increases the potential risk of contrast-induced nephropathy related to CTPA or even contra-indicates this test, and ventilation-perfusion lung scan (which can be performed in patients with severe renal failure) provides a high proportion of inconclusive results in older patients. Moreover, ruling out PE based on clinical probability and a simple blood test could contribute to reduce the time spent in the emergency department and the costs related to PE diagnostic work-up. Indeed, a previous study had shown that D-dimer measurement with conventional cut-off was highly cost-saving in patients less than 80 years, but not in patients over 80 years. Using an age-adjusted D-dimer cut-off dramatically increases the proportion of patients in whom PE can be ruled out and is thus highly likely to reduce the costs of PE diagnosis in the emergency department.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All consecutive patients admitted to the emergency department with suspected PE defined as acute onset of new or worsening shortness of breath or chest pain without any other obvious etiology in whom PE has been considered ruled out by negative D-dimers using an age-adjusted cut-off will be screened for inclusion. Those with non-high probability and negative D-dimer (PE excluded by the non-invasive strategy using "new" D-dimer cut-off) will be included and followed-up for 3 months. The aim of including both patients above and under 50 years of age is to be able to compare the difference in thromboembolic event rates between patients with a D-dimer level between 500 µg/L and their age-ajusted cut-off and those with a D-dimer < 500 µg/L.
Key inclusion criteria (1 listed)
- Consecutive out patients with suspected PE in whom PE has been considered ruled out by negative D-dimers using an age-adjusted cut-off.
Key exclusion criteria (5 listed)
- Life expectancy less than 3 months.
- Geographic inaccessibility for follow-up.
- Therapeutic anticoagulation for any indication.
- Pregnancy.
- Age less than 18.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionThis is an observational study, without any specific intervention. | Other | – |
Primary outcome
The incidence of symptomatic thromboembolic events during follow-up in patients with PE excluded based on a negative D-dimer using the age-adjusted cutoff
Time frame: Three months
Adjudicated objectively confirmed pulmonary embolism and/or deep vein thrombosis
1 secondary outcome
Additional diagnostic yield of the age-adjusted D-dimer cut-off compared with the standard cut-off of 500µg/L
Time frame: Three months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2021.
- Background: PubMed 24643601Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le Gal G. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014 Mar 19;311(11):1117-24. doi: 10.1001/jama.2014.2135.
- Derived from this study: PubMed 33939529Robert-Ebadi H, Robin P, Hugli O, Verschuren F, Trinh-Duc A, Roy PM, Schmidt J, Fumeaux T, Meyer G, Hayoz D, Carron PN, Salaun PY, Sarasin F, Rutschmann O, Le Gal G, Righini M. Impact of the Age-Adjusted D-Dimer Cutoff to Exclude Pulmonary Embolism: A Multinational Prospective Real-Life Study (the RELAX-PE Study). Circulation. 2021 May 4;143(18):1828-1830. doi: 10.1161/CIRCULATIONAHA.120.052780. Epub 2021 May 3. No abstract available.
Related trials for Pulmonary Embolism
Not yet recruiting
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
RecruitingObservational study
Clinical Management and Outcomes After Lung Scintigraphy for Suspected Pulmonary Embolism in the Emergency Department
Pulmonary Embolism (Diagnosis)
Active, not recruitingPhase 3
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Pulmonary Embolism
Not yet recruitingPhase 4
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
Pulmonary Embolism Acute
Not yet recruitingPhase 2
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
Erythrocytosis, Pulmonary Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Helia Robert-Ebadi, MD principal investigator
Geneva University Hospitals and Faculty of Medicine
10 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Embolism, run by University Hospital, Geneva at 10 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in France, Switzerland, Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence of symptomatic thromboembolic events during follow-up in patients with PE excluded based on a negative D-dimer using the age-adjusted cutoff (time frame: Three months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02601846, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2021.